Strides Pharma#39;s step-down subsidiary in Singapore received AUD 94 million or Rs 525 crore as the deferred consideration for the sale of the Company’s Australian operations in 2019. The proceeds will be utilized for deleveraging the balance sheet, the firm said in an exchange filing.
English 
हिन्दी